Schrodinger Announces Research Collaboration with Pfizer
FREMONT, CA: Schrödinger, a developer of chemical simulation software for pharmaceutical and biotechnology research has announced about its research partnership with Pfizer- a research based biopharmaceutical company. Under this agreement, the companies will work mutually to develop a computational model to predict the key properties suitable for biotherapeutic candidates.
Both the companies will perform tasks in effort to develop an innovative model for predictions of properties related to biotherapeutic candidates. Pfizer will generate the experimental data with which the computational model is to be developed and provide it to the Schrödinger team. The teams from both the companies will work together to determine the future systems to apply, test and improve the developing technology. “Schrödinger has made key scientific breakthroughs in recent years in the areas of protein and ligand structure determination and potency prediction that have made a significant impact on drug discovery,” says, Dr. Ramy Farid, President at Schrödinger.
Schrödinger provides products ranging from general molecular modeling programs to a full-featured suite of drug design software. Its software with predictive power allows scientists to accelerate their research and development activities reducing research costs.
Pfizer combines science and global resources to deliver innovative therapies that significantly improve lives. The firm also collaborates with healthcare providers, governments and local communities to support and expand access to reliable and affordable health care.